Luminita-Cornelia Andrei-Selmer, PhD, PM

Area of interest

Identifying the interactions of a given protein and activity-based protein profiling for biochemical pathway discovery have emerged as valuable information in the post–genomic era. I am interested in the investigations that support biomarkers identification and selection of specific effectors – such as peptides, antibodies or engineered cells – for therapeutic purposes. I am interested in mapping specific expression of proteins, their interaction with other biomolecules, quantification of the binding to modulators or substrates[i], the pathophysiology and clinical aspects. My approaches in basic and then translational research (biomarker research and immunotherapy) involved in vivo imaging and in vitro protein interaction analysis as based on their (natural) affinity:

a. Function and topography of disintegrin proteases and substrates in ontogenesis of the brain. [ii]

b. Development of tools to evaluate biomarkers for Alzheimer’s diseases and their implication in the immunotherapy[iii], [iv], [v].

c. Role of junction adhesion molecules in inflammation and lung cancer cells during metastasis[vi]

d. Specific interaction between neutrophil specific antigen CD177 and endothelial CD31[vii]. Demonstration that the heterophilic binding CD177-CD31 occurs during the inflammation and is stronger than the homophylic interaction CD31-CD31. HO-1 regulation is CD31 dependent. [viii]

e. Alloantibody-mediated platelet depletion in sera of neonatal alloimmune mediated thrombocytopenia patients [ix], [x]

My cooperation projects involved academic research institutes and partners from the pharma / biotech industry.

[i]  L Muhl, S.P. Galuska, K. Oörni, L. Hernandez-Ruiz, L.C. Andrei-Selmer, R. Geyer, Preissner KT, F.A. Ruiz, P. T. Kovanen, Ruiz FA and S.M. Kanse, High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease, FEBS J. 276 (17): 4828-39, (2009)

[ii] data not published

[iii] R. Dodel, K. Balakrishnan, K. Keyvani, O. Deuster, F. Neff, L. C. Andrei-Selmer, S. Roskam, C Stuer, Yl-Abed, M. Balzer-Geldsetzer, W. Oertel, Y. Du and M. Bacher, Naturally occurring autoantibodies against ß-amyloid: investigating their role in transgenic animal and in-vitro models of Alzheimer’s disease, J. Neuroscience 31(15): 5847-54, (2011)

[iv] D. Bartnik*, S. A. Funke*, L. C. Andrei-Selmer*, M. Bacher, R. Dodel and D. Willbold, Differently Selected d-Enantiomeric Peptides Act on Different Abeta Species., Rejuvenation Res. 13(2-3): 202-5, (2010)

[v] K.Balakrishnan, L.C. Andrei-Selmer, T. Selmer, M. Bacher and R. Dodel

Comparison of intravenous immunoglobulins for naturally occurring antibodies against β-amyloid,  J Alzheimers Dis. 20(1):135-43, (2010)

[vi] S. Santoso, V. Orlova, K. Song, U. J. H. Sachs, C. L. Andrei-Selmer, T. Chavakis, The homophilic interaction of JAM-C mediates tumor cell-endothelial cell interactions. J Biol Chem. 280, 36326-33, (2005)

[vii] U.J.H. Sachs, L. C. Andrei-Selmer, A. Maniar, C. Paddock, P.J. Newman, T. Chavakis, and S. Santoso The neutrophil specific antigen CD177 is a novel counter-receptor for endothelial PECAM-1 (CD31). J. Biol. Chem. 282 (32): 23603-12, (2007)

[viii] H. Saragih, E. Zilian, Y. Jaimes, A. Paine, C. Figueiredo, B Eiz-Vesper, R. Blasczyk, J. Larmann, G. Theilmeier, L. C. Andrei-Selmer, J Becker, S Santoso and S Immenschuh

PECAM-1 dependent heme oxygenase-1 regulation via a Nrf2-Mediated Pathway in endothelial cells, Thrombosis and Haemostasis, 111(6): 1077-88, (2014)

[ix] Socher I*. L. C. Andrei-Selmer*, G. Bein and S. Santoso, Low-avidity HPA-1a alloantibodies in severe neonatal alloimmune thrombocytopenia are detectable with surface-plasmon resonance technology, Transfusion 49(5): 943-52, (2009)

[x] S. Santoso, H. Kroll, L. C. Andrei-Selmer, I. Socher, A. Rankin, E. Kretzschmar, N. A. Watkins, W.H. Ouwehand

A naturally occurring Leu₃₃Val mutation in beta3 integrin impairs the HPA-1a epitope: The third allele of HPA-1,

Transfusion 46 (5), 790-9, (2006)

_______

* equal contribution

Affiliation

OncoGen Centre, Timisoara

E-mail: (IT Department)